Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1382 studies found for:    Doxorubicin (liposomal) OR Doxil[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Completed AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Conditions: Cancer;   Carcinoma;   Fallopian Tube Cancer;   Gynecological Malignancies;   Metastases;   Oncology;   Ovarian Cancer;   Solid Tumors;   Tumors
Interventions: Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin;   Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin;   Drug: B1: AMG 386 10 mg/kg + Topotecan;   Drug: B3: AMG 386 15mg/kg + Topotecan
2 Terminated MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)
Condition: Ovarian Cancer
Intervention: Drug: MK-4827 + pegylated liposomal doxorubicin
3 Terminated
Has Results
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Carcinoma
Interventions: Drug: Pazopanib;   Drug: Doxil
4 Withdrawn Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas
Conditions: Solid Tumors;   Lymphomas
Interventions: Drug: Recombinant human TNF-α;   Drug: Liposomal doxorubicin;   Drug: Caelyx
5 Completed A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3;   Drug: liposomal doxorubicin
6 Terminated
Has Results
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
Condition: Refractory Multiple Myeloma
Interventions: Drug: liposomal doxorubicin;   Drug: bortezomib;   Drug: dexamethasone;   Drug: cyclophosphamide
7 Withdrawn Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Condition: Breast Cancer
Interventions: Drug: Liposomal Doxorubicin;   Drug: Seliciclib
8 Active, not recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Drug: Veliparib
9 Unknown  Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Interventions: Drug: Liposomal doxorubicin;   Drug: Cisplatin
10 Active, not recruiting Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
Interventions: Drug: Bortezomib;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride
11 Active, not recruiting Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: Liposomal Doxorubicin+Gemcitabine;   Drug: FOLFOX4
12 Completed Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: sargramostim;   Drug: methotrexate;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: vincristine sulfate
13 Completed Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Condition: Sarcoma
Intervention: Drug: temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
14 Completed Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Conditions: Primary Peritoneal Carcinoma;   Epithelial Ovarian Carcinoma;   Neoplasms, Ovarian;   Fallopian Tube Cancer
Intervention: Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
15 Completed Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Filgrastim;   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate
16 Completed Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
Conditions: Sarcoma, Kaposi;   HIV Infections
Intervention: Drug: Doxorubicin hydrochloride (liposomal)
17 Recruiting Women's Triple-Negative First-Line Study: Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
18 Completed Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate
19 Recruiting Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma
Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
20 Completed Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement
Condition: Advanced Cancer
Interventions: Drug: Cisplatin;   Drug: Liposomal Doxorubicin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years